In line with its strategy to identify and strike RNAi collaborations with key academic researchers, CytRx said last week that it had inked a partnership with Massachusetts General Hospital, one of Harvard Medical School’s teaching hospitals, to develop drugs for amyotrophic lateral sclerosis. The deal comes on the heels of a separate alliance CytRx formed with UMass Medical School to develop a cure for the disease.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.